Sicherheit und Wirksamkeit der Linken -Bündel -Zweiggebiets -Stimulation im Vergleich zu herkömmlichen Herz -Resynchronisierungstherapie bei Herzinsuffizienz (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Jacqueline Beaulieu
- Telefonnummer: 1-800-227-3422
- E-Mail: jacqueline.beaulieu@bsci.com
Studienorte
-
-
Alabama
-
Huntsville, Alabama, Vereinigte Staaten, 35801
- Rekrutierung
- Heart Center Research, LLC
-
Kontakt:
- John Jennings, Dr.
-
Hauptermittler:
- John Jennings, Dr.
-
Mobile, Alabama, Vereinigte Staaten, 36608
- Rekrutierung
- Mobile Infirmary Medical Center
-
Kontakt:
- Ernest Matthew Quin, Dr.
-
Hauptermittler:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Rekrutierung
- Mayo Clinic Phoenix
-
Kontakt:
- Mayank Sardana, MD
-
Hauptermittler:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, Vereinigte Staaten, 72401
- Rekrutierung
- Arrhythmia Research Group
-
Kontakt:
- Devi Nair, Dr.
-
Hauptermittler:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, Vereinigte Staaten, 92037
- Rekrutierung
- Scripps Memorial Hospital
-
Kontakt:
- Nicolas Olson, MD
-
Hauptermittler:
- Nicolas Olson, MD
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars Sinai Medical Center
-
Hauptermittler:
- Ashkan Ehdaie, MD
-
Kontakt:
- Ashkan Ehdaie, MD
-
Oakland, California, Vereinigte Staaten, 94609
- Rekrutierung
- Alta Bates Summit Medical Center
-
Kontakt:
- Rajan Shah, Dr.
-
Hauptermittler:
- Rajan Shah, Dr.
-
Santa Monica, California, Vereinigte Staaten, 90404
- Rekrutierung
- Pacific Heart Institute
-
Kontakt:
- Stephen Tang, MD
-
Hauptermittler:
- Stephan Tang, MD
-
Torrance, California, Vereinigte Staaten, 90505
- Rekrutierung
- Torrance Medical Center
-
Hauptermittler:
- Gene Kim, MD
-
Kontakt:
- Gene Kim, MD
-
Ventura, California, Vereinigte Staaten, 93003
- Rekrutierung
- Cardiology Associates Medical Group, Inc.
-
Kontakt:
- Jonathan Dukes, Dr.
-
Hauptermittler:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- Washington Hospital Center
-
Kontakt:
- Cyrus Hadadi, MD
-
Hauptermittler:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, Vereinigte Staaten, 34239
- Rekrutierung
- Sarasota Memorial Hospital
-
Kontakt:
- Antonio Moretta, Dr.
-
Hauptermittler:
- Antonio Moretta, Dr.
-
Tampa, Florida, Vereinigte Staaten, 33613
- Rekrutierung
- AdventHealth Tampa
-
Hauptermittler:
- Kenneth Yamamura, MD
-
Kontakt:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30309
- Rekrutierung
- Piedmont Hospital
-
Kontakt:
- Kavita Krishnasamy, MD
-
Hauptermittler:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University Hospital
-
Kontakt:
- Anand Shah, MD
-
Hauptermittler:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Rekrutierung
- St. Luke's Idaho Cardiology Associates
-
Kontakt:
- Justice Oranefo, MD
-
Hauptermittler:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Rekrutierung
- University of Chicago
-
Kontakt:
- Shrinath Yeshwant, MD
-
Hauptermittler:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, Vereinigte Staaten, 60540
- Zurückgezogen
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46250
- Rekrutierung
- Community Heart and Vascular Hospital
-
Kontakt:
- Krishna Malineni, MD
-
Hauptermittler:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa Hospitals and Clinics
-
Hauptermittler:
- Paari Dominic, MD
-
Kontakt:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40207
- Rekrutierung
- Baptist Hospital East Louisville
-
Hauptermittler:
- Kevin Parrott, MD
-
Kontakt:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, Vereinigte Staaten, 02720
- Rekrutierung
- Southcoast Physicians Group
-
Kontakt:
- Arnoldas Giedrimas, MD
-
Hauptermittler:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan Hospitals
-
Hauptermittler:
- Thomas Crawford, MD
-
Kontakt:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, Vereinigte Staaten, 49525
- Rekrutierung
- Corewell Health
-
Kontakt:
- Jawad Wassim, MD
-
Hauptermittler:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Zurückgezogen
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, Vereinigte Staaten, 56303
- Zurückgezogen
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07932
- Rekrutierung
- Morristown Medical Center
-
Kontakt:
- Michael Katz, MD
-
Hauptermittler:
- Michael Katz, MD
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12211
- Rekrutierung
- Capital Cardiology Associates
-
Kontakt:
- Rizwan Alimohammad, MD
-
Hauptermittler:
- Rizwan Alimohammad, MD
-
Flushing, New York, Vereinigte Staaten, 11355
- Rekrutierung
- New York Hospital Queens
-
Kontakt:
- Seth Goldbarg, Dr.
-
Hauptermittler:
- Seth Goldbarg, Dr.
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Weill Cornell Medical University
-
Kontakt:
- Jim Cheung, Dr.
-
Hauptermittler:
- Jim Cheung, Dr.
-
New York, New York, Vereinigte Staaten, 14621
- Rekrutierung
- Rochester General Hospital
-
Kontakt:
- Dmitry Chuprun, MD
-
Hauptermittler:
- Dmitry Chuprun, MD
-
Syracuse, New York, Vereinigte Staaten, 13057
- Rekrutierung
- SUNY-Upstate Medical University
-
Kontakt:
- Jorge Romero, MD
-
Hauptermittler:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Rekrutierung
- Sanger Heart and Vascular Institute
-
Kontakt:
- Navid Nafissi, MD
-
Hauptermittler:
- Navid Nafissi, MD
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Kontakt:
- Daniel Friedman, MD
-
Hauptermittler:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43219
- Rekrutierung
- Mount Carmel Health System
-
Kontakt:
- Kamel Addo, MD
-
Hauptermittler:
- Kamel Addo, MD
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Rekrutierung
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
Kontakt:
- Anish Amin, MD
-
Hauptermittler:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Penn Presbyterian Medical Center
-
Kontakt:
- John Bullinga, MD
-
Hauptermittler:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, Vereinigte Staaten, 18702
- Rekrutierung
- Geisinger Wyoming Valley
-
Hauptermittler:
- Pugazhendhi Vijayaraman, MD
-
Kontakt:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57108
- Rekrutierung
- Avera Heart Hospital of South Dakota
-
Kontakt:
- Christopher Stanton, Dr.
-
Hauptermittler:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37205
- Rekrutierung
- St.Thomas Health
-
Kontakt:
- Ricardo Lugo, MD
-
Hauptermittler:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, Vereinigte Staaten, 75093
- Rekrutierung
- Heart Hospital Baylor Plano
-
Kontakt:
- Mustafa Dohadwala, MD
-
Hauptermittler:
- Mustafa Dohadwala, MD
-
Tyler, Texas, Vereinigte Staaten, 75701
- Rekrutierung
- Christus Trinity Mother Frances Health System
-
Kontakt:
- Stanislov Weiner, Dr.
-
Hauptermittler:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Rekrutierung
- University of Virginia Medical Center
-
Hauptermittler:
- Pamela Mason, MD
-
Kontakt:
- Pamela Mason, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
Experimental: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Zeitfenster: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
Zeitfenster: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Win ratio composite assessment
Zeitfenster: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Zeitfenster: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
Zeitfenster: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- C2403
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .